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ARTICLE OPEN
Extracellular vesicle-associated Aβ mediates trans-neuronal
bioenergetic and Ca2+-handling deficits in Alzheimer’s
disease models
Erez Eitan1, Emmette R Hutchison1, Krisztina Marosi1, James Comotto1, Maja Mustapic1, Saket M Nigam1, Caitlin Suire1,
Chinmoyee Maharana1, Gregory A Jicha2, Dong Liu1, Vasiliki Machairaki3, Kenneth W Witwer4, Dimitrios Kapogiannis1
and Mark P Mattson1,5
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder in which aggregation-prone neurotoxic amyloid β-peptide
(Aβ) accumulates in the brain. Extracellular vesicles (EVs), including exosomes, are small 50–150 nm membrane vesicles that have
recently been implicated in the prion-like spread of self-aggregating proteins. Here we report that EVs isolated from AD patient
cerebrospinal fluid and plasma, from the plasma of two AD mouse models, and from the medium of neural cells expressing
familial AD presenilin 1 mutations, destabilize neuronal Ca2+ homeostasis, impair mitochondrial function, and sensitize neurons to
excitotoxicity. EVs contain a relatively low amount of Aβ but have an increased Aβ42/ Aβ40 ratio; the majority of Aβ is located on
the surface of the EVs. Impairment of lysosome function results in increased generation of EVs with elevated Aβ42 levels. EVs may
mediate transcellular spread of pathogenic Aβ species that impair neuronal Ca2+ handling and mitochondrial function, and may
thereby render neurons vulnerable to excitotoxicity.
npj Aging and Mechanisms of Disease (2016) 2, 16019; doi:10.1038/npjamd.2016.19; published online 22 September 2016
INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease that accounts for 60–70% of cases of dementia in the
aging population. The disease has two pathological hallmarks:
extracellular amyloid β (Aβ) peptide aggregates that form
extracellular plaques, and intracellular hyperphosphorylated Tau
protein aggregates that form neurofibrillary tangles. Pathogenic
forms of Aβ and Tau can impair synaptic function and trigger a
series of events leading to neuronal death.1 Although the causes
of Aβ and Tau aggregation and cytotoxicity in the common
sporadic late-onset cases of AD are unclear, 1–5% of AD patients
exhibit early-onset disease resulting from mutations in the
amyloid precursor protein (APP) or presenilin 1 (PS1; an enzyme
that cleaves APP to generate Aβ).1,2 Studies of the consequences
of expressing AD PS1 and APP mutations in cultured cells
and transgenic mice have provided insight into the molecular
and cellular alterations underlying the pathogenesis of AD.3 In
particular, aggregating Aβ and Tau can impair mitochondrial
function and perturb neuronal Ca2+ handling, thereby rendering
synapses and neurons vulnerable to degeneration.4–8
Recently, it has been suggested that pathogenic forms of Aβ
and Tau can propagate between cells in a prion-like manner,
such that a misfolded protein can pass from a donor to a recipient
cell and serve as a seed for further protein conversion and
aggregation.9,10Although it has been shown that injection of Aβ
from either biological or synthetic sources into the mouse brain
can accelerate endogenous Aβ aggregation throughout the brain,
the mechanism responsible for this propagation of the pathology
is unclear.11 Extracellular vesicles (EVs), including exosomes, are
small-membrane vesicles released from all cell types and found in
bodily fluids, are one potential mechanism by which misfolded
proteins and protein aggregates might spread through
tissues.12,13 EVs can contain several aggregation-prone proteins
responsible for neurodegenerative disease including Aβ,14 APP
C-terminal fragments,15 Tau,16 α-synuclein,17 SOD118 and the
prion protein.19 Moreover, two EV markers, Alix and Flotillin, have
been found in amyloid plaques, suggesting a role of EVs in plaque
generation.14,20 EVs are secreted by either direct budding of the
plasma membrane or fusion of multivesicular bodies with the
plasma membrane.21 Multivesicular bodies have been reported as
an important site of Aβ generation, leading to the suggestion that
EVs may also be a site of APP processing into Aβ.14,22 Interestingly,
EVs released by healthy neurons can interact with extracellular Aβ
and facilitate its fibrillation and clearance by microglia.23–26
Although EVs from AD patients and various AD models contain
some amount of Aβ (refs 14,15,27) the contribution of EVs to Aβ
production and the pathogenesis of AD is not clear. Here we
report that EVs isolated from the cerebrospinal fluid (CSF) of
patients with sporadic, late-onset AD or released from
cultured human neurons harboring a pathogenic PS1 mutation
are toxic to cerebral cortical neurons by a mechanism involving
EV surface-associated Aβ. EVs with neurotoxic Aβ impair neuronal
Ca2+ handling and mitochondrial function. The release of EVs
with neurotoxic Aβ is increased when lysosome function is
compromised, suggesting that the impaired lysosome function
that occurs in neurons in AD28 may trigger EV-mediated
trans-neuronal propagation of neurodegenerative cascades.
1Laboratory of Neurosciences, National Institute on Aging, NIH, Baltimore, MD, USA; 2Sanders-Brown Center on Aging, and Department of Neurology, University of Kentucky
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RESULTS
Extracellular vesicles from PS1 mutant cells contain a relatively low
concentration of Aβ, but are enriched in Aβ42 relative to Aβ40
To investigate the effects of pathogenic PS1 mutations on
EV-associated Aβ, we first isolated EVs from the culture medium
of H4 glioblastoma cell lines genetically engineered to express
either the PS1Δ9 mutation (H4PS1Δ9) or wild-type PS1 (H4PS1WT) in
an inducible manner. The expression of PS1Δ9 or PS1WT was
induced by tetracycline for 5 days, and EVs were isolated from the
culture medium by ultracentrifugation.29 The EVs were evaluated
according to the published guidelines30 by transmission electron
microscopy, immunoblot analysis and NTA particle size analysis
(Figure 1a–d). The vast majority EVs were 50–250 nm in diameter,
with the most abundant size being about 130 nm (Figure 1c). The
EVs contained high amounts of the EV marker proteins flotillin-1
and CD9 (Figure 1d). We found that the PS1Δ9 mutation did not
alter EV morphology, size distribution or expression of these EV
markers. The levels of Aβ40 and Aβ42 associated with EVs and free
in the culture medium were measured by a Mesoscale Discovery
(MSD, Rockville, MD, USA) immunoassay (Figure 1e). Aβ40
and Aβ42 were significantly lower in the EV fraction than in the
EV-depleted medium fraction and in the parent cell lysates
(Figure 1e). Given that the Aβ42/Aβ40 ratio may be a better
predictor of AD than the individual concentrations of Aβ40 and
Aβ42, we calculated the Aβ42/Aβ40 ratio31,32 and found that
the Aβ42/Aβ40 ratio in EVs was significantly higher than in
EV-depleted medium or cell lysate (Figure 1f).
To further characterize the association of Aβ with EVs, we
examined EVs released from cultured human neurons derived from
induced pluripotent stem cells generated from fibroblasts taken
from a patient with AD caused by a PS1 mutation (hNPS1A246E
neurons) and control neurons generated from fibroblasts from a
neurologically normal human subject.33 EVs isolated from culture
medium were evaluated by NTA and immunoblotting with
antibodies against the EV markers flotillin-1 and CD9
(Supplementary Figure 1). The levels of Aβ42 and Aβ40 associated
with EVs were significantly lower than Aβ42 and Aβ40 levels in the
EV-depleted medium (Figure 1e), but the Aβ42/Aβ40 ratio was
significantly higher in EVs compared to EV-depleted medium
(Figure 1f). As expected, the levels of Aβ42 were higher in H4PS1Δ9
cell lysate, culture medium and EVs compared to H4PS1WT cells, and
the level of Aβ42 was higher in hNPS1A246E medium than hNPS1WT
medium (Supplementary Figure 2).
We next determined whether EV-associated Aβ is contained
within EVs and/or on the outer surface of their membrane. EVs were
incubated with 1 mg/ml trypsin for 1 h prior to two rounds of
120,000g centrifugation to purify EVs. The trypsin treatment
reduced the amount of Aβ42 and Aβ40 associated with EVs
isolated from H4PS1Δ9 cells by 82% (Figure 1g). These results
indicate that most EV-associated Aβ is located on the outer surface
of the EV membrane. It has been reported previously that neuronal
EVs contain several Aβ-binding proteins and lipids.34–36 Thus, it is
possible that the Aβ is not released together with the EVs but
becomes associated with EVs extracellularly. However, incubating
EVs derived from H4PS1WT cells with EV-depleted medium derived
Figure 1. Human neural cells expressing familial Alzheimer’s disease (AD) presenilin 1 mutations release extracellular vesicles (EVs) with elevated
levels of Aβ42 on their outer surface. (a, b). Transmission electron microscope images of EVs released from H4 cells expressing either the δ9 PS1
mutation (a) or wild-type (WT) PS1 (b) Bar = 100 nm. (c) Size distribution of EVs released from H4 cells expressing mutant (red) or wild type
(blue) PS1 measured by Nanocyte particle tracking. (d) Immunoblot demonstrating enrichment of EV markers CD9 and Flotillin-1 in EVs released
from H4 cells, and relatively low amounts of amyloid β-peptide (Aβ) in EVs relative to H4 cell lysate. (e, f) Levels of Aβ42 and Aβ40 (e) and the
Aβ42/Aβ40 ratio (f) in cells, EVs and EV-depleted medium from neurons differentiated from induced pluripotent stem cell (iPSC) that were
generated from fibroblasts from a patient with familial AD (PS1 mutation; n= 5 cultures), and from H4 human neuroglioma cells expressing
mutant PS1 (8 separate cultures). (g) Levels of Aβ40 and Aβ42 in EVs isolated from the medium of cultured H4Ps1Δ9 cells, H4Ps1WT cells,
H4Ps1WT EVs incubated in H4Psn1Δ9 EV-depleted medium, or H4Psn1Δ9 EVs incubated with trypsin (n= 3). (h) Levels of Aβ40 and Aβ42 in EVs
isolated from the medium of cultured H4Psn1Δ9 cells that had been treated for 24 h with vehicle (control; n=5) or bafilomycin A (n=5), or in
which cathepsin D was knocked down using CRISPR Cas9 technology (n= 3). *Po0.05, **Po0.01, ***Po0.001.
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from H4PS1Δ9 resulted in only a very small increase in the levels of
EV-associated Aβ (Figure 1g), suggesting that Aβ becomes
associated with vesicles prior to their release from cells.
Accumulating evidence indicates that Aβ production can occur
in the endosomal system, including within multivesicular
bodies.14,22,37 We hypothesized that if the association of Aβ with
vesicles occurs in the endosomal system, inhibiting the lysosome
would increase the release of Aβ42-containing EVs.38 Incubating
H4PS1Δ9 cells for 24 h with 200 μmol/l of bafilomycin A significantly
increased EV secretion by 1.4-fold (data not shown), and the
concentration of Aβ associated with EVs was increased by about
3-fold (Figure 1h); the Aβ42/Aβ40 ratio was also increased
significantly (Supplementary Figure 3). Bafilomycin A is a V-ATPase
inhibitor and, while being a potent inhibitor of lysosomal function,
it also has an effect on endosomal pH levels, which could affect
the activity of β-secretase and γ-secretase.38,39 Therefore, we
measured the effect of bafilomycin A on Aβ concentration in the
cells and culture medium. The level of Aβ in the cells was
increased similarly to that in EVs, but there was no significant
difference in the level of Aβ in culture media from control and
bafilomycin A-treated cells (Supplementary Figure 3A). To verify
the effect of lysosome inhibition on EV-associated Aβ, we
employed Cas9 with a sgRNA targeted to disrupt the cathepsin
D gene (Supplementary Figure 3B). H4 cells, in which cathepsin D
was knocked down, secreted EVs with threefold more Aβ and had
a higher Aβ42/Aβ40 ratio compared with EVs secreted from
control H4 cells (Figure 1h and Supplementary Figure 3C).
EVs derived from PS1 mutant cells are neurotoxic
Having established that PS1 mutant neurons release EVs that have
higher levels of Aβ on their surface, we performed a series of
experiments to determine whether these EVs are neurotoxic.
When EVs isolated from the culture medium of H4PS1Δ9 cells were
added to primary rat cortical neurons at a concentration of ~ 300
EVs/neuron, significant reductions of neuronal viability occurred
within 48 h (Figure 2a,b). Interestingly, incubation of primary
cortical neurons with EV-depleted medium (containing about
10-fold more Aβ42 than EVs) or with 10 μmol/l of recombinant
Aβ42 had a similar effect on neuronal viability as did the lower
amount of Aβ associated with EVs released from cells expressing
mutant PS1 (Figure 2a,b). It was previously reported that Aβ42
sensitizes neurons to glutamate-induced excitotoxicity.40 We,
therefore, determined whether EVs isolated from the medium of
mutant PS1-expressing cells affect the vulnerability of neurons to
excitotoxicity. Cortical neurons were exposed to EVs for 24 h,
followed by the addition of 100 μmol/l glutamate for an additional
24 h. Parallel neuronal cultures were exposed to EVs, glutamate or
Figure 2. Extracellular vesicles (EVs) isolated from the medium of cultured human neural cells expressing mutant PS1 are neurotoxic. (a, b) Rat
primary cortical neurons were exposed to the indicated treatments for 24 h and cell viability was evaluated by MTT (a) and LDH (b) assays
(n= 3–6 separate cultures). (c) Thioflavin S (green), and 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; blue) staining demonstrates that
treating cortical neuron cultures with Psn1Δ9-derived EVs results in the accumulation of Thioflavin S reactive aggregates. (d) Cleaved caspase
3 staining (green) and DAPI (blue) staining showing increased cell death following incubation of cortical neuron cultures with Psn1Δ9-derived
but not WT EVs. (e). Reduced MAP2 staining (green; a neuronal protein) is observed in rat neuronal cultures incubated with Psn1Δ9-derived
EVs. DAPI (blue). (f). Quantification of fluorescence intensities of primary neuronal cultures that had been exposed for 48 h to EVs derived from
H4 cells expressing mutant PS1 and then stained with Thioflavin S, cleaved caspase 3 and MAP2. Values are expressed as fold difference from
the value for neurons exposed to EVs from control H4 cells (n= 6 cultures). (g) Images showing PKH-labeled EVs (red) and DAPI (blue) staining
in cortical neurons that had been incubated for 6 h in the presence of EVs released from H4 cells expressing WT PS1 or mutant PS1 (PS1MT).
(h, i). Levels of MTT reduction and LDH release (cytotoxicity) in cortical neurons that that had been incubated for 48 h in the presence of EVs
from neurons derived from induced pluripotent stem cell (iPSC) generated from fibroblasts from a patient with familial Alzheimer’s disease
(AD; IPS), EV-depleted iPSC culture medium, or Aβ1–42 (10 μmol/l). UT, untreated control cultures. Cultures were co-treated with glutamate
(100 nmol/l) or vehicle as indicated. Values are the mean and s.e.m. (n= 6 cultures). *Po0.05, **Po0.01. Aβ, amyloid β-peptide.
Exosomes propagate Abeta neurotoxicity
E Eitan et al
3
Published in partnership with the Japanese Society of Anti-Aging Medicine npj Aging and Mechanisms of Disease (2016) 16019
vehicle for 48 h. Glutamate alone induced a 15–20% reduction in
viability, but in combination with EVs from H4PS1Δ9 cells, neuronal
viability was reduced by 50–56% (Figure 2a,b). To further examine
whether the neurotoxicity of H4PS1Δ9 derived EVs is mediated by
Aβ, the ability of an antibody against Aβ (6E10) to protect neurons
was examined; the Aβ antibody abolished the neurotoxicity of the
EVs (Figure 2a,b). The latter result suggests that the neurotoxic
property of EVs is mediated by Aβ on their surface.
To further investigate the neurotoxicity of EV-associated Aβ, we
incubated neurons for 48 h with EVs derived from H4PS1Δ9 cells
followed by fixation and staining with Thioflavin S (to label Aβ
aggregates with a β-sheet structure), and antibodies against
cleaved-caspase 3 (a marker of apoptosis) and the neuron-specific
cytoskeletal protein MAP2 (Figure 2c–f). The fluorescent intensities
of both Thioflavin S and cleaved-caspase 3 were significantly
greater (4- and 3.5-fold higher, respectively) in neurons treated
with EVs from H4PS1Δ9 cells compared with neurons treated
with EVs from H4PS1wt cells, while the amount of MAP2
immunoreactivity was 40% lower (Figure 2f). The levels of
Thioflavin S were also greater in neurons treated with H4PS1wt
derived EVs compared with untreated neurons. To determine the
relative numbers of EVs internalized by the neurons, EVs were
stained with the lipophilic dye PKH26 before incubation with
cortical neurons, and internalized EVs were imaged by confocal
microscopy (Figure 2g). There was no apparent difference in the
amount of H4PS1Δ9 and H4PS1WT EVs internalized by the neurons
(Figure 2g and quantification in Supplementary Figure 4A).
To better quantify the levels of internalization, different
amounts of labeled EVs were added to the culture medium,
and the increase in flourecence intensity was measured after
4 and 24 h of incubation. EV concentration-dependent increases in
internalization was seen at both time points (Supplementary
Figure 4B,C). Incubating the labeled EVs with Aβ antibody only
slightly reduced their internalization (Supplementary Figure 4B,C)
and thus the ability of the antibody to completely block
neurotoxicity is probably not due to reduced internalization. EVs
from hNPS1A246E neurons were relatively less neurotoxic than EVs
from H4PS1Δ9cells (Figure 2h,i). This difference could be due to the
two different PS1 mutations (PS1 A246E compared with PS1Δ9), to
different amounts or conformations of Aβ42 on the EV surfaces, or
to differential biological activities of the EVs independent of Aβ
(for example, it has been reported that EVs released from stem
cells have trophic effects41).
AD cell-derived exosomes cause calcium dysregulation and
mitochondrial impairment, and can trigger neuronal apoptosis
To determine the cause of the observed neurotoxicity of EVs
released from cells expressing AD mutant PS1, we examined the
effects of these EVs on neuronal Ca2+ handling following
glutamate exposure and on cellular metabolism using the
Seahorse mitochondrial function assay (Agilent Technologies,
Santa Clara, CA USA). Primary cortical neurons were incubated
for 48 h with EVs released from H4PS1Δ9 or H4PS1wt cells, or with
EVs released from hNPS1A246E neurons. The [Ca2+]I responses to
glutamate in neurons treated with EVs from H4PS1Δ9, H4PS1wt,
hNPS1wt neurons, hNPS1A246E neurons or synthetic Aβ42 are shown
in Figure 3a–f. Incubating neurons with EVs from PS1 mutant cells
did not induce any increase in the magnitude of the peak [Ca2+]I
response (Figure 3b,e), but did cause a significant increase in the
response duration (37% and 21% increases for EVs from H4PS1Δ9
cells and iPS neurons, respectively; Figure 3c,f). While adding the
Aβ blocking antibody did not have an effect on amplitude of
[Ca2+]I response (Figure 3b), it did enhance recovery of [Ca
2+]I
following glutamate exposure (Figure 3a,c), suggesting that the
effect of EVs on recovery of [Ca2+]I is mediated by the Aβ on the
surface of the EVs. This analysis may underestimate the increase in
[Ca2+]I response duration caused by EVs, because the [Ca
2+]I in rat
cortical neurons treated with EVs released from H4PS1Δ9 and
induced pluripotent stem cells-derived neurons did not recover to
50% of maximum (Figure 3g).
We next performed a Seahorse mitochondrial function assay on
neurons treated with EVs released from H4PS1Δ9 and H4PS1wt cells,
and found significantly reduced mitochondrial functionality as a
result of incubation with EVs released from cells expressing the
PS1Δ9 mutation (Figure 3h,i). The effects of H4PS1Δ9 cell-derived
EVs in reducing basal and maximal respiration, and ATP levels,
were similar to the reductions in these mitochondrial variables in
neurons exposed to synthetic Aβ42 (Figure 3h,i). Collectively, the
data are consistent with a role of EV surface-associated Aβ42 in
the neurotoxic effects of EVs.
Extracellular vesicles in mouse models of AD and AD patient CSF
exhibit a high Aβ42/40 ratio
To determine whether EVs isolated from biological fluids of AD
patients and animal models exhibited Aβ-related neurotoxic
properties similar to EVs released from cultured cells expressing
mutant PS1, we measured the concentrations of Aβ42 and Aβ40 in
EVs isolated from plasma samples from six transgenic APP/PS1
double-mutant transgenic mice,42 five 3xTgAD mice43 and nine
age-matched wild-type mice. The levels of Aβ42 and Aβ40 were
significantly lower in EVs and EV-depleted plasma samples from
wild-type mice compared with transgenic mice (Supplementary
Figure 5). The levels of Aβ42 and Aβ40 were significantly lower in
plasma-derived EVs than in EV-depleted plasma (Figure 4a), but
the Aβ42/Aβ40 ratio was significantly higher in the EVs compared
with EV-depleted plasma (Figure 4b). Next, we isolated EVs from
CSF samples from six patients with sporadic, late-onset AD, six
mild cognitive impairment (MCI) patients and six age-matched
control subjects. EVs isolated from CSF were highly enriched in the
EV markers flotillin-1 (FLOT1) and Alix (Supplementary Figure 6A),
but not the intracellular (non-exosomal) protein early endosome
antigen 1 (EEA1; data not shown). Interestingly, the EV size
distribution in all CSF samples showed two populations, one with
a mean diameter of about 70 nm, a size typical of exosomes, and
another with a mean size of about 170 nm, which may be
microvesicles.21 The concentration of EVs in the CSF of AD, MCI
and healthy individuals were similar and much lower than their
concentration in plasma (Supplementary Figure 6D).
We next measured the levels of Aβ42 and Aβ40 in CSF-derived
EVs and found that these were significantly lower in EVs compared
with EV-depleted CSF and plasma samples of AD patients
(Figure 4c). The Aβ42/Aβ40 ratio was significantly higher in EVs
derived from CSF and plasma of AD patients compared with
EV-depleted CSF and plasma samples (Figure 4d). The levels of
Aβ42 and Aβ40 associated with EVs were also low in CSF samples
from subjects with MCI and aged-matched neurologically normal
healthy subjects, but the Aβ42/Aβ40 ratio was significantly higher
in EVs isolated from AD patients CSF compared with EVs from
control subjects CSF (Supplementary Figure 7). To determine
whether EV-associated Aβ from AD patient CSF was contained
within EVs and/or on their surface, EVs were incubated with
1 mg/ml trypsin for 1 h prior to two rounds of 120,000g
centrifugation to purify EVs. Similar to EVs released from H4PS1Δ9
cells (Figure 1g), we observed a 75% reduction in the amount of
Aβ42 and Aβ40 associated with EVs treated with trypsin compared
with EVs not treated with trypsin (Figure 4e).
CSF-derived exosomes cause calcium dysregulation and
mitochondrial impairment and can trigger neuronal apoptosis
The finding of high Aβ42/Aβ40 ratio of CSF-derived EVs from
patients with sporadic, late-onset AD prompted us to evaluate
their potential neurotoxicity. EVs isolated from CSF were added to
the medium bathing cultured cerebral cortical neurons (~100 EVs
per neuron), and 48 h later cell viability was measured with MTT
Exosomes propagate Abeta neurotoxicity
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and LDH assays. Exposure of neurons to CSF-derived EVs resulted
in a significant reduction of neuronal viability in MTT (Figure 5a)
and LDH (Figure 5b) assays. The magnitude of reduction of
viability of CSF EV-treated neurons was similar to that measured
in neurons exposed to 10 μmol/l Aβ42, whereas EVs isolated
from cultured rat cortical neurons exhibited no neurotoxicity
(Figure 5a,b). Moreover, EVs isolated from the CSF of healthy
human subjects did not induce significant toxicity (Supplementary
Figure 7). CSF EVs from AD patients and synthetic Aβ42
significantly increased the vulnerability of cortical neurons to
glutamate excitotoxicity, and these adverse effects of AD CSF EVs
and synthetic Aβ42 were abolished by treatment with an Aβ
antibody (Figure 5a,b). To determine whether EVs from AD CSF
cause Aβ aggregation and apoptosis, neurons were stained with
thioflavin S and a cleaved-caspase 3 antibody (Figure 5c,d).
Thioflavin S staining was undetectable in untreated neurons (not
shown) and in neurons treated for 48 h with EVs isolated from the
medium of cultured rat cortical neurons, but was evident in
neurons incubated for 48 h with human CSF-derived EVs, and to a
lesser extent in neurons treated with Aβ1–42 (Figure 5c). Whereas
no neurons exhibited cleaved-caspase 3 immunoreactivity in
cortical neuron cultures treated with EVs released from healthy
cortical neurons, many neurons exhibited cleaved caspase 3
immunoreactivity in cortical neurons treated with AD CSF-derived
EVs or Aβ42 (Figure 5c,d).
To provide further insight into the role of EV-associated Aβ in
neuronal degeneration in AD, we plotted the concentration of
Aβ42 in EVs isolated from cell culture medium and human subject
CSF as a function of the relative neurotoxicity of EVs from the
same sources (Supplementary Figure 8). The most neurotoxic EVs,
those from AD patient CSF and those released from cells
expressing mutant PS1, also had the highest amounts of Aβ42
associated with them. In contrast, EVs released from control
human cells were the least neurotoxic and had the lowest
amounts of Aβ42 associated with them. There was a highly
significant correlation of EV Aβ42 level and neurotoxicity of the
EVs (Supplementary Figure 8).
We next performed Ca2+ imaging experiments in which [Ca2+]I
responses to glutamate were measured in vehicle-treated control
rat cortical neurons and in neurons that had been preincubated
Figure 3. Extracellular vesicles (EVs) generated by human neural cells expressing mutant PS1 impair cellular Ca2+ handling and mitochondrial
function in cerebral cortical neurons. (a) Preincubation of rat cortical neurons with H4Psn1Δ9-derived EVs for 24 h resulted in a greater
sustained Ca2+ response to glutamate (10 μmol/l) stimulation (arrow indicates the time of glutamate application) compared with neurons
preincubated with EVs from H4Psn1WT cells. Values are the mean and s.e.m. of measurements made in 20 neurons per culture in 7 different
cultures. (b, c) Quantification of peak amplitude (b) and time to reach 50% recovery (c) following glutamate stimulation in cortical neurons
that had been pretreated for 24 h with EVs (H4D9 cells with either wild type (WT) or Δ9 PS1; H4(PS1Δ9)+AβAb was a condition in which the
EVs were incubated with an amyloid β-peptide (Aβ) antibody (6E10). Values are the mean and s.e.m. of measurements made in neurons from 7
different cultures. (d) Alzheimer’s disease (AD) patient iPSC-derived neuronal EVs induce Ca2+ dysregulation following stimulation with
glutamate (10 μmol/l; arrow indicates the time of glutamate application). Values are the mean and s.e.m. of measurements made in three
different cultures (20 neurons per culture). (e, f) Peak amplitude (e), and time to reach 50% recovery (f) following glutamate stimulation in rat
cortical neurons pretreated for 24 h with EVs from AD patient or WT induced pluripotent stem cells (iPSC)-derived neurons (Aβ condition is rat
cortical neurons incubated with 10 μmol/l synthetic Aβ1–42). (g). Analysis of the percentage of cortical neurons unresponsive to glutamate
following incubation with mutant or wild-type (WT) EVs derived from H4 cells and IPSC-derived neurons (n= 7 for H4 EVs treated neurons and
n= 3 for IPC EVs treated neurons). (h) Representative Seahorse oxygen consumption assay showing mitochondrial impairment 24 h following
treatment with H4Psn1Δ9-derived EVs or 20 μmol/l Aβ1–42. (i) Basal oxygen-consumption rate, maximal consumption rate and ATP
production in cortical neurons that had been treated for 24 h with H4Psn1Δ9-derived EVs or 20 μmol/l Aβ1–42. Values are the mean and s.e.m.
from measurements made in five independent cultures. *Po0.05, **Po0.01.
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for 48 h with CSF EVs from AD, MCI and control subjects, or Aβ42.
Neurons incubated with AD CSF-derived EVs demonstrated a
significant 25 ± 9% increase in the peak amplitude of the
glutamate-induced elevation of [Ca2+]I; this effect of AD CSF EVs
was prevented by treatment with an Aβ antibody (Figure 6a,b).
The time required for the [Ca2+]I to return to 50% of the peak
[Ca2+]I response to glutamate was not significantly affected by AD
CSF EVs, although there was a trend towards slower recovery of
[Ca2+]I (Po0.072; Figure 6c). We next measured neuronal oxygen
consumption to evaluate mitochondrial function in cortical
neurons exposed for 48 h to CSF EVs from AD, MCI and control
subjects (Figure 6d shows the results of a representative
experiment, and Figure 6e is the combined data from six
experiments). Neurons treated with AD patient CSF-derived EVs
or with Aβ42 had significantly reduced basal and maximal
respiration, and reduced ATP production (Figure 6e). The adverse
effects of AD CSF EVs on mitochondrial function were abolished
by treatment with an Aβ antibody (Figure 6e).
DISCUSSION
We found that compared with various control EVs, EVs released
from cultured human neurons and cell lines expressing mutant
PS1, and EVs isolated from the CSF of sporadic, late-onset AD
patients, have elevated amounts of Aβ42 (predominantly located
on their surface) and can induce degeneration of cerebral cortical
neurons. EVs from sporadic, late-onset AD patient CSF and EVs
released from cells expressing mutant PS1 impaired mitochondrial
function, destabilized neuronal Ca2+ homeostasis, and rendered
cortical neurons vulnerable to excitotoxicity. The adverse effects of
the AD patient and experimental model EVs on neuronal Ca2+
handling, mitochondrial function and cell viability were prevented
by treatment with an Aβ antibody, indicating a key role for EV
surface-associated Aβ in pathogenic effects of AD EVs.
Our findings provide novel insight into potential roles of EVs in
propagating Aβ-related pathology and associated neuronal
degeneration. It has been suggested that AD pathology spreads
in a trans-neuronal manner with prion-like characteristics,9,10 and
this possibility is supported by data from mouse model
experiments where inoculation with synthetic Aβ or Aβ-containing
brain homogenate accelerate development of pathology.11
Interestingly, we found that although the majority of Aβ in CSF,
plasma and culture medium is not associated with EVs, the EVs
have significantly higher Aβ42/Aβ40 ratio and are toxic to primary
neurons, suggesting a possible role for EVs in AD pathogenesis.
The toxic effect of EVs is specific to AD (even in sporadic,
late-onset cases) or at least to neurodegenerative disease, because
CSF EVs from healthy subjects exhibited little or no neurotoxicity.
We found that EVs isolated from CSF, plasma and culture
medium from human neural cells expressing pathogenic PS1
mutations contained lower concentrations of Aβ40 and Aβ42
compared with the fluid from, which they were isolated. However,
the Aβ42/Aβ40 ratio was significantly higher in EVs compared with
the fluids from which they were isolated. These findings are of
interest with regards to AD pathogenesis as the Aβ42/Aβ40 ratio
has been found to be a more reliable biomarker for AD than Aβ42
or Aβ40 alone.44 Moreover, mixtures of Aβ42 and Aβ40 with a
higher Aβ42/Aβ40 ratio aggregate more vigorously and are more
neurotoxic than mixtures with a low Aβ42/Aβ40 ratio.45,46 It was
recently reported that EVs of neuronal origin isolated from the
blood of AD patients prior to their diagnosis contain elevated
levels of Aβ42 (and p-Tau) compared with EVs from healthy
control subjects.47 We found that EVs have a relatively high
Aβ42/40 ratio and are potent in disrupting neuronal Ca2+
homeostasis, impairing mitochondrial function and triggering
apoptosis. However, whether Aβ associated with EVs has a critical
role in the pathogenesis of AD remains to be determined.
Recent findings suggest that EVs can transport pathogenic
forms of Aβ, pTau and α-synuclein into recipient neurons via
internalization.14,16,17 We found that EVs isolated from sporadic,
late-onset AD patient CSF or from the culture medium of human
cells expressing mutant PS1, are internalized by cerebral cortical
neurons. The recipient neurons accumulate Thioflavin S-reactive
protein aggregates, and manifest impaired Ca2+ handling and
mitochondrial dysfunction. However, in contrast to the
presumption that Aβ is located inside EVs,13 we found that
Figure 4. Extracellular vesicles (EVs) isolated from cerebropspinal fluid (CSF) and plasma of Alzheimer’s disease (AD) patients, and from plasma
in two AD mouse models, exhibit a high Aβ42/40 ratio. Concentrations of Aβ40 and Aβ42 were measured in samples of EVs (+EV) and
corresponding fluids from which they were isolated (− EV). (a, b). Results of analyses of blood plasma samples from 3xTgAD and 2xTgAD mice
(n= 5 3xTgAD and n= 6 2xTgAD mice). (c, d). Results of analyses of CSF and blood plasma samples from AD patients (n= 6 patients).
(e) Quantification of Aβ40 and Aβ42 levels in EVs isolated from the CSF of AD patients. The EVs were incubated with or without with trypsin
prior to the analysis (EV preparations from three different AD patients). **Po0.01, ***Po0.001. Aβ, amyloid β-peptide.
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Aβ1–42 is predominantly located on the external surface of EVs.
Previous findings suggest that Aβ aggregation is enhanced when
the pathogenic peptide is associated with cell membranes,
particularly membranes rich in sphingomyelin, gangliosides and
cholesterol, so-called lipid rafts.48–52 During the process of its
aggregation on the membrane surface, Aβ can generate reactive
oxygen species that induce membrane lipid peroxidation,53,54
which can impair the function of membrane ion-motive ATPases,
and glucose and glutamate transporters, and thereby render
neurons vulnerable to excitotoxicity and apoptosis.55–57 Our
data suggest that similar to aggregating synthetic Aβ1–42, EV
surface-associated Aβ can increase the vulnerability of neurons to
excitotoxicity and apoptosis by a mechanism involving impaired
Ca2+ regulation.
It has been suggested that neuronal EVs can scavenge
extracellular Aβ by binding of Aβ to EV proteins such as cystatin
c,35 insulin-degrading enzyme,34,58 the cellular prion protein26 and
ganglioside GM1.36 We incubated EVs derived from cells expres-
sing wild-type PS1 with EV-depleted medium from PS1Δ9 mutant
cells and found a small but significant increase in Aβ associated
with the EVs; however, Aβ levels in the latter EVs were
considerably lower than EVs released from PS1Δ9 mutant cells.
Our findings therefore suggest that while EVs have some capacity
to interact with extracellular Aβ, much of the Aβ associated with
EVs released from neural cells is present prior to their release.
Accumulating evidence suggests that endosomes are a major site
of APP processing to generate Aβ species.59 Endosomes may
therefore be relatively enriched in Aβ that may associate with the
intraluminal vesicles that can then be released from cells as EVs
(exosomes). It has been shown that aggregation of proteins on the
plasma membrane can trigger membrane budding and release of
EV containing high amounts of the aggregated protein.60
Tetraspanins61,62 and syndecan heparan sulfate proteoglycans,
together with Alix and syntenin,63 are involved in the formation
and release of such EVs. Hence, it is possible that Aβ aggregation
on the plasma and/or endosomal membranes results in Aβ
secretion with EVs, and that such EVs are enriched in Aβ42 and
Aβ40 in amounts and a stoichiometry45,46 that render them highly
pathogenic.
In AD patients, active lysosomal proteases are associated with
plaques and degenerating neurons, which also display other
characteristics of lysosomal dysfunction including increased
expression of hydrolases such as cathepsin D and accumulation of
lysosomes.64,65 Familial AD PS1 mutations disrupt lysosomal
acidification and autophagy.66 Cells in brain tissue samples from
sporadic, late-onset AD patients also display a marked increase in
immature autophagic vacuoles,67 a phenotype possibly related to
lysosome impairment.28 Disruption of autophagy through
heterozygous deletion of Beclin1 in an AD mouse model resulted
in both intracellular accumulation of Aβ and increased amyloid
plaque deposition,68 suggesting that autophagy is a major
facilitator of Aβ clearance. However, crossing an AD mouse model
with a mouse line defective in autophagy (ATG7 knockout mice)
resulted in accumulation of intracellular Aβ and reduced Aβ
secretion,69 suggesting that autophagy may also have a role in Aβ
secretion. Previous studies have shown that mutations in PS1
cause lysosome impairment,66 EVs contain lysosomal proteins,70
and EV marker proteins such as Alix and flotillin-1 are present in
AD amyloid plaques.14,20 We found that inhibition of autophagy
(by exposure to bafilomycin A or CRISPR-Cas9-mediated
knockdown of cathepsin D) in cells expressing mutant PS1
resulted in increased release of EVs with elevated amounts of
Aβ42, suggesting that impaired autophagy may result in the
release of pathogenic EVs in AD. These Aβ42-laden EVs are
neurotoxic as indicated by their adverse effects on neuronal Ca2+
homeostasis, mitochondrial function, and vulnerability to
excitotoxicity and apoptosis. Data from previous studies of
postmortem brain tissue from sporadic, late-onset AD patients
and of experimental cell culture and animal models, strongly
support roles for impaired neuronal Ca2+ handling, mitochondrial
Figure 5. Alzheimer’s disease (AD) patient CSF-derived extracellular vesicles (EVs) are neurotoxic. (a, b) Results of MTT and LDH assays
demonstrating that 48 h incubation of rat neurons with AD cerebrospinal fluid (CSF) EVs (at a concentration of 100 EVs per neuron)
diminished neuronal survival by an amount similar to that of neurons exposed to Aβ1–42 (10 μmol/l). AD CSF EVs also increased neuronal
vulnerability to glutamate during a 24 h incubation (n= 6 cultures). Where indicated, cultures were co-treated with Aβ antibody 6E10 (1 μg
antibody per 107 EVs). (c, d) Cultured cortical neurons were incubated for 24 h in the presence of fluorescently tagged EVs that had been
isolated from the culture medium of rat cortical neurons or from AD CSF (100 EVs per neuron), or with 10 μmol/l Aβ1–42. Cortical neurons
were then stained with Thioflavin S or anti-cleaved caspase 3. Representative images are shown. Similar results were obtained in six separate
experiments. *Po0.05. Aβ, amyloid β-peptide.
Exosomes propagate Abeta neurotoxicity
E Eitan et al
7
Published in partnership with the Japanese Society of Anti-Aging Medicine npj Aging and Mechanisms of Disease (2016) 16019
dysfunction and apoptosis-like cell death in AD.1,4,71 Future
studies involving animal models and human subjects will be
required to elucidate the roles of Aβ-laden EVs in AD pathogenesis
and their potential as a therapeutic target.
MATERIALS AND METHODS
Animals
APP/PS1 double-mutant transgenic mice (2xTgAD mice; B6C3-Tg(APPswe,
PS1Δ9)85Dbo)42 and 3xTgAD mice (B6 129-Psentm1Mpm Tg, APPSwe,
tauP301L1Lfa) mice43 were maintained under a 12 h light/12 h dark cycle
with food and water available ad libitum. Mice were killed with an overdose
of isoflurane anesthesia and blood was collected directly from the heart.
All procedures were approved by the National Institute on Aging Animal
Care and Use Committee and complied with NIH guidelines.
Cell culture, experiments treatments, transfection and cell viability
assays
Dissociated embryonic rat cortical cells cultures were established and
maintained using methods similar to those described previously.72
Neurons were grown in polyethylenmine-coated plastic culture dishes or
coverslips. Cultures were maintained at 37 °C (5% CO2/95% air
atmosphere) in Neurobasal medium (Gibco 21103-049) containing
B-27 supplement (Invitrogen) plus 1% antibiotic (Gibco 15240-062,
Invitrogen). One quarter of the medium was replaced every 3 days and
the cells were maintained for 7–10 days in culture prior to performing
experiments. Human neuroglioma (H4TR) cells stably expressing wild-type
(WT) PS1 or mutant PS1 (delta E9 mutation) under the control of a
tetracycline responsive element were cultured in Dulbecco's modified
Eagle medium (Gibco #12800-058) supplemented with 10% fetal bovine
serum (Tet-tested, Thermo Fisher Scientific #SH30070.03T, Carlsbad,
CA, USA), 50 μg/ml Zeocin (Invitrogen, #R250-01) and 2.5 μg/ml blasticidin
(Invitrogen, #R210-01), and were maintained at 37 °C (5% CO2/95% air
atmosphere). To induce expression of the mutant form of PS1, the cells
were induced with 100 ng/ml tetracycline (Sigma-Aldrich #T7660, St Louis,
MO, USA) for 3–5 days. Human neurons were differentiated from induced
pluripotent stem cells that had been derived from fibroblasts taken from a
patient with early-onset AD caused by a PS1 mutation (A246E) using
methods described previously.33
Cells were grown to 50–60% confluency prior to transfection. The
following plasmids were transfected using Lipofectamine LTX (Invitrogen
94756) according to the manufacturer’s protocol: Rab11-FIP3 CRISPR/Cas9
Double Nickase (sc-405735-NIC) and cathepsin D CRISPR/Cas9 (sc-400207).
Bafilomycin A (Baf A) was dissolved in dimethylsulfoxide to generate a
stock solution of 400 mmol/l and stored at − 20 °C. When thawed, the Baf A
was diluted 1:2,000 in cell culture medium. In order to examine the effects
on cell viability, rat primary neurons were plated in a 96-well plate (30,000
cells per well) and treated as indicated. Neurons were exposed to
EVs isolated from CSF or plasma (at a concentration calculated to result in a
EV/neuron ratio of 100:1) or H4-derived EVs (EV/neuron ration of 300:1) for
48 h, and in some experiments 100 μmol/l glutamate was added after 24 h
of EV treatment. Following 48 h EV incubation, 50 μl of medium was taken
from each well and centrifuged at 300g for 5 min prior to measurement of
LDH activity in the supernatant according to the manufacturer’s
instructions (Roche 11644793001, Indianapolis, IN, USA). The MTT solution
(Promega #G3581, Madison, WI, USA) was diluted 1 to 5, and 50 μl was
added to each well. The MTT signal (light absorbance at 570 nm) was
measured 0.5 to 4 h later using a Biotek Synergy H1 plate reader.
Human CSF and plasma samples
CSF from six patients with sporadic, late-onset AD, MCI and age-matched
neurologically normal subjects were obtained from the University of
Kentucky AD Center. The latter CSF samples were drawn from living AD
and MCI patients, and age-matched control subjects using standard
National Alzheimer Coordinating Center and Alzheimer Disease
Neuroimaging Initiative protocols.73,74 Samples were from: three female
and three male AD patients (age range from 74–84 years); three
female and three male MCI patients (age range from 65–92 years); and
four female and two male control subjects (age range from 74–83 years).
Figure 6. Alzheimer’s disease (AD) patient cerebrospinal fluid (CSF)-derived extracellular vesicles (EVs) impair neuronal Ca2+ regulation and
mitochondrial function. (a) Graph showing relative intracellular Ca2+ levels (Fluo 8 fluorescence intensity before and during exposure to
glutamate (100 μmol/l). (b, c) Graphs showing amplitudes of peak Ca2+ responses to glutamate (b) and the time required for the Fluo 8
fluorescence intensity to recover to 50% of the peak level (c). (d, e) Results of Seahorse analysis of mitochondrial respiration in cultured
neurons that had been pretreated for 24 h with EVs isolated from the medium bathing healthy primary rat cortical neurons (100 particles per
neuron), 10 μmol/l amyloid β-peptide (Aβ) or EVs isolated from the CSF of AD patients (100 particles per neuron). (d) Results of a representative
experiment. (e) Data from six experiments. *Po0.05; **Po0.01.
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CSF from four additional AD and two MCI patients as well as plasma
samples were obtained from the Clinical Research Unit of the National
Institute on Aging (CRU-NIA) of Harbor Hospital (Baltimore, MD, USA). The
diagnosis of AD used the criteria of probable AD as defined by the current
NIA-AA criteria,76 although the diagnosis of MCI was based on the criteria
set forth by the 2nd International Working Group on MCI75.
Calcium imaging
Neurons that had been growing on glass coverslips for 8 days were treated
with EVs at indicated concentrations for 2 days. Neurons were then
incubated for 20 min in the presence of Fluo 8 (0.05 ng/ml) and then
washed twice with Locke’s buffer. Neuronal Fluo 8 fluorescence was
imaged using a Zeiss (Oberkochen, Germany) LSM 510 confocal
microscope. The baseline fluorescence signal was recorded for 40–100 s,
100 μmol/l glutamate was then added, and the fluorescence signal was
measured for at least an additional 400 s.
Isolation of extracellular vesicles
CSF or plasma (0.5 ml) samples were centrifuged at 2,300g for 30 min to
remove cell debris. The supernatant was transferred to a Beckman
(Brea, CA, USA) ultracentrifugation tube (#326823) and diluted with 3 ml
sterile filtered (0.22 μm filter Millex, EMD Millipore (Billerica, MA, USA)
#SLG5033SS) phosphate-buffered saline (PBS) prior to centrifugation for
2.5 h at 120,000g (SW55 rotor K= 48). The supernatant was carefully
removed and the pellet was resuspended in lysis buffer for protein
quantification or Neurobasal medium for functional assays. Rat and human
neurons were grown without serum, and H4 neuroblastoma cells were
washed with PBS and medium replaced with EV-depleted FBS prior to
treatments and medium collection for isolation of EVs.76 EVs were isolated
from approximately 30 ml of medium (~25–30 million cells). The medium
was centrifuged at 500g for 10 min to remove dead cells, then the
supernatant was centrifuged at 2,300g for 10 min to remove cell debris
and the supernatant was stored at − 20 °C. Once thawed (at room
temperature), the medium was centrifuged at 120,000g for 2.5 h (SW28
rotor K=246). Following this the supernatant was removed for use as an
EV-depleted control and the pellet was suspended in 3.5 ml sterile filtered
PBS and centrifuged again at 120,000g for 2.5 h (SW55 rotor K= 48).29 The
supernatant was carefully removed and the pellet containing EVs was
resuspended in either lysis buffer for protein quantification or Neurobasal
medium for functional assays.
EV labeling with PKH26/67
Membranes of EVs were labeled with the fluorescent probe PKH26 using a
kit purchased from Sigma (#PKH26GL). EV pellets were suspended in 100 μl
of buffer C prior to addition of 100 μl 2 × PKH26 solution and incubated for
2 min, followed by addition of PBS containing 2% bovine serum albumin
(Sigma #A-3912). The labeled EVs were centrifuged twice at 120,000g for
1 h (SW55i rotor K = 48) with an intervening wash to ensure removal of
unbound dye. The indicated amounts of EVs were added to the cells and
incubated for the 4, 6 or 24 h. As a control, PBS with the same
concentration of PKH26 was centrifuged under the same conditions and
added to the cells as negative control. The internalization was quantified
by confocal microscopy or using a fluorescence plate reader.
Transmission electron microscopy
A drop of EV preparations (suspended in PBS) was added to a freshly
ionized 300 mesh Formvar/Carbon-coated grid and incubated for 5 min to
allow adherence of the EVs to the grid. The grid was then washed through
5–7 puddles of ddH2O; and negatively stained in 2% aqueous uranyl
acetate for 30 s. Images were acquired using a FEI Tecnai G2 Spirit
transmission electron microscope with TWIN Lens operating at 100 kV and
an Olympus Soft Imaging System Megaview III digital CCD.
Quantification of EV numbers
EV suspensions were diluted 1:20 or 1:200 to permit counting in the range
of 3–15 × 108 per ml with an NS500 nanoparticle tracking analysis system
(NanoSight, Amesbury, UK). The EVs were visualized by their scattering of a
focused laser beam and the collection of the scattered light using a
standard optical microscope fitted with a CCD video camera. Five
exposures of 20 s each were recorded from fields chosen randomly by a
computer operating with NanoSight software, Malvern Instruments
(Malvern, United Kingdom), which enables measurement of EV size and
numbers.
Immunofluorescence, microscopy and image analysis
Cells were grown on glass coverslips in a 24-well plate. Following the
indicated treatment, cells were washed twice with PBS and were fixed in a
solution of 4% paraformaldehyde in PBS for 20 min. Fixed cells were
incubated in blocking solution (0.3% Triton X-100 and 10% normal goat
serum in PBS) for 30 min, and then incubated overnight at 4 °C with
antibodies against cleaved-caspase 3 (D175, Cell Signaling, Danvers, MA,
USA), MAP2 (Hm2, Sigma M9942), Aβ (6E10 SIG39320-200). The cells were
then washed three times with PBS and incubated with fluorescently
tagged anti-rabbit or anti-mouse secondary antibodies (Invitrogen) in
blocking solution for 1 h at room temperature. The cells were then washed
twice with PBS and, if indicated, were stained with 0.02% Thioflavin S
(Sigma T-1892) for 8 min and then washed three times with 80% ethanol,
twice with water and two times with PBS. Nuclei were stained with 4′,6-
diamidino-2-phenylindole dihydrochloride (Sigma #32670) in PBS for
10 min. All coverslips were then washed with PBS and mounted on
microscope slides in an anti-fade medium (Vector Laboratories, Burlin-
game, CA, USA). Images were acquired using a Zeiss LSM 510 confocal
microscope with a × 40 objective. Quantification of the staining intensity
and area, and evaluation of co-localization were performed using Fiji
software.75
Protein extraction and immunoblots
Cells were washed twice with sterile PBS and scraped into a 15 ml tube
prior to centrifugation at 700g for 10 min. The supernatant was then
removed and the pellet was resuspended in 100–200 μl of lysis buffer
(M-PER) with protease inhibitors (Complete Mini, Sigma) and incubated on
ice for 30 min before centrifugation at 10,000g for 25 min. The supernatant
was stored at − 80 °C. Protein extracts from EVs was prepared by
resuspension of the EV pellet in lysis buffer (M-PER) with protease
inhibitors, followed by vortexing for 10 s (samples were stored at − 80 °C).
After thawing on ice the samples were sonicated in a water bath for 5 min
and centrifuged for 25 min at 10,000g. The supernatant was transferred to
a new tube and used directly or stored at − 80 °C. Equal amounts of protein
for each sample were resuspended in sample buffer (Life NP0008) and
analyzed by polyacrylamide gel electrophoresis (Life technologies NOVEX
NP0302BOX or NP0321BOX) and subsequent immunoblotting. Immuno-
complexes were detected by enhanced chemiluminescence (Pierce 32106).
The following antibodies were used for immunoblots: monoclonal anti-Alix
(3A9, Cell Signaling 0512015) ), polyclonal anti-FLOT1 (Abcam ab133497,
Cambridge, UK), polyclonal anti-CD9 (H-110, Santa Cruz SC9148, Dallas,
TX, USA), anti-Aβ (6E10 SIG39320-200), and anti-mouse or anti-rabbit
secondary antibodies (Jackson Laboratories 715-036-151, 711-036-152, Bar
Harbor, MA, USA).
Statistical analysis
Results are expressed as mean and s.e.m. of the indicated number of EVs
preparation or independent neuronal cultures. The differences in numbers
of cells that responded to glutamate treatment was determined using
χ2-test. Comparisons of Aβ concentration and ratios between EVs and
EV-depleted fluids was calculated by Mann–Whitney U-test, unless there
were more than two groups and then one-way analysis of variance was
used. Neurotoxicity, calcium imaging and Seahorse data were evaluated
using two-way analysis of variance followed by the Bonferroni post hoc
test. The correlation between the EVs Aβ concentration and their toxicity
was determined by linear regression. These analyses were performed using
the Prism software package (Graphpad Software, San Diego, CA, USA).
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